ERBB2 and breast cancer: NEOSPHERE clinical trial results showed that the rate of pathological complete response (pCR) was higher for HER2 positive BC patients treated with a combination of pertuzumab, trastuzumab, and docetaxel compared to patients treated with trastuzumab and docetaxel [123].